Evidence map›Paper›PMID 39470875›Full record

Observational studyAdvances in therapy2024

Efficacy and Safety of Non-Ablative Dual Wavelength Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Single-Center Prospective Study.

Salvatore Giovanni Vitale, Stefania Saponara, Antonio Giuseppe Succu, Gilda Sicilia, Konstantinos Martsidis, Maurizio Nicola D'Alterio, Stefano Angioni

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06503003 (Non-ablative Diode Laser Therapy for Genitourinary Syndrome of Menopause), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06503003 unknown statusnot on this map

Non-ablative Diode Laser Therapy for Genitourinary Syndrome of Menopause: A Prospective Study on Efficacy, Safety, and Quality of Life and Sexuality Impact

TypeobservationalSponsorUniversity of CagliariRan2023 to 2025Enrolled50ConditionsGenitourinary Syndrome of MenopauseArmsLeonardo® Diode laser
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Salvatore Giovanni VitaleDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.ORCID 0000-0001-6871-6097
Stefania SaponaraDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy. saponara.stef@gmail.com.ORCID 0000-0003-1022-0958
Antonio Giuseppe SuccuDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Gilda SiciliaDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Konstantinos MartsidisDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Maurizio Nicola D'AlterioDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Stefano AngioniDivision of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study evaluates the efficacy and safety of non-ablative diode laser therapy for genitourinary syndrome of menopause (GSM) in post-menopausal women unable to use hormonal therapies.

methodsA pilot prospective study was conducted from September 2023 to April 2024, involving 22 post-menopausal women aged 45-73 years. Participants underwent three sessions of diode laser treatment with the Leonardo

resultsSignificant improvements were observed in VHIS, increasing from 12 to 19.27 at 6 months (p < 0.001). GSM symptoms improved significantly: vaginal dryness scores decreased from 7.72 ± 2.37 to 3.72 ± 2.53, burning sensation scores dropped from 6.00 ± 3.22 to 1.90 ± 1.81, and dyspareunia scores reduced from 8.09 ± 2.11 to 3.90 ± 2.58 (all p < 0.016). Sexual function improved, indicated by FSFI-6 scores increasing from 12.27 ± 7.29 to 19.30 ± 6.24 (p < 0.016) and SQOL-F scores rising from 63.18 ± 22.93 to 71.45 ± 23.31. No adverse events were reported.

conclusionNon-ablative diode laser therapy is effective and safe for managing GSM symptoms in post-menopausal women, offering significant symptom relief and enhancing sexual health without serious side effects. Further research with a larger cohort and extended follow-up is needed to confirm these findings.

trial registrationClinical Trials ID NCT06503003.

Indexed as

Lasers, SemiconductorQuality of LifeAgedFemaleFemale Urogenital DiseasesHumansLow-Level Light TherapyMenopauseMiddle AgedPilot ProjectsProspective StudiesSyndromeTreatment OutcomeDiode laserGenitourinary syndrome of menopauseMenopauseSexual functionVaginal atrophy

Identifiers

PMID39470875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.